adalimumab (preferred products) — Highmark
Psoriatic Arthritis (PsA) – enthesitis and/or dactylitis associated
Initial criteria
- age ≥ 18 years
- diagnosis of enthesitis and/or dactylitis associated with PsA
- prescribed by or in consultation with a rheumatologist or dermatologist
- experienced therapeutic failure or intolerance to at least one NSAID or a local glucocorticoid injection OR all NSAIDs and all local glucocorticoid injections are contraindicated
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy